Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro

Author： Racanelli A.L.   Gibbs S.K.   Zondlo S.C.   Seiffert D.A.   Friedman S.M.   Feuerstein G.Z.  

Publisher： Elsevier

ISSN： 0049-3848

Source： Thrombosis Research, Vol.110, Iss.2, 2003-05, pp. : 99-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Antiplatelet Efficacy of the Platelet GPIIb/IIIa Antagonist, DMP754 in Non-Human Primates - Receptor binding affinity & specificity

By Mousa S.A.   Bozarth J.   Youssef A.   Levine B.  

Thrombosis Research, Vol. 89, Iss. 5, 1998-03 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Antiplatelet and Antithrombotic Effects of Orbofiban, a New Orally Active GPIIb/IIIa Antagonist, in Guinea Pigs

By Ogawa T.   Sugidachi A.   Naganuma H.   Asai F.  

Thrombosis Research, Vol. 97, Iss. 5, 2000-03 ,pp. : 307-315

Elsevier

Access to resources Recommend Favorite

Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease

By  

Current Vascular Pharmacology, Vol. 6, Iss. 1, 2008-01 ,pp. : 29-36

Bentham Science Publishers

Access to resources Recommend Favorite

The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro

By Scholz Thomas   Zhao Lian   Temmler Uta   Bath Philip   Heptinstall Stan   Lösche Wolfgang  

Platelets, Vol. 13, Iss. 7, 2002-11 ,pp. : 401-406

Informa Healthcare

Access to resources Recommend Favorite

The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIIa antagonist

By Aoki T.   Cox D.   Senzaki K.   Seki J.   Tanaka A.   Takasugi H.   Motoyama Y.  

Thrombosis Research, Vol. 81, Iss. 4, 1996-02 ,pp. : 439-450

Elsevier

Access to resources Recommend Favorite